A decade of experience with an inpatient pneumococcal vaccination program

Robke, Jill T.; Woods, Mark

doi:10.2146/ajhp080638

Cited by 18 publications

(24 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pneumococcal and influenza vaccination rates for the intervention group were 71% and 55%, respectively, compared with 10% and 15% in the control group. Another study evaluated pharmacists who screened patients for eligibility and contacted the physician for authorization to vaccinate . This resulted in an increase in the pneumococcal vaccination rate from 47% in the control group ( n = 124) to 74% in the intervention group ( n = 107).…”

Section: Discussionmentioning

confidence: 99%

“…Our study is unique in that a pharmacy resident drove the protocol, adding to the significant literature already published supporting pharmacy involvement to increase vaccination rates. [14][15][16][17][18][19][20] Sokos et al evaluated a pharmacy-driven pneumococcal vaccination standing order program which screened an average of 800 patients/month and resulted in an increased vaccination rate from 15% to 69% over a two-year period. 15 Bourdet et al evaluated a pharmacy standing order protocol for influenza and pneumococcal vaccinations.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A pharmacy resident‐driven pneumococcal vaccination protocol increases vaccination rates in hospitalized patients over 65 years

Wells

Monte

Prescott

et al. 2019

J Am Coll Clin Pharm

View full text Add to dashboard Cite

Introduction Pneumococcal disease remains a leading cause of serious illness in adults aged 65 years and older. Despite this, pneumococcal vaccination rates remain suboptimal in this population. Objectives To implement a pharmacy resident‐driven pneumococcal vaccination protocol and to assess vaccination rates and the return on investment (ROI) for patients age 65 years and older admitted to an internal medicine service at an academic medical center. Methods A retrospective, single center review of a newly implemented pharmacy resident‐driven pneumococcal vaccination protocol targeting patients age 65 years and older admitted to an internal medicine service was conducted. The primary outcome was the percentage of eligible patients, as defined by the Center for Disease Control vaccination guidelines, who received a pneumococcal vaccine prior to discharge over a 60‐day period. The secondary outcome was ROI from the hospital perspective, which was calculated as follows: net profit (defined as total revenue—total cost) divided by total cost and then multiplied by 100. Pneumococcal vaccination rates and ROI data were presented descriptively. Results A total of 84 patients were included in the pharmacy resident‐driven protocol, 37 (42%) of whom were up‐to‐date on their pneumococcal vaccinations. Among the remaining 51 vaccine‐eligible patients, 33 (64.7%) were vaccinated prior to hospital discharge: 19/33 (57.6%) received the pneumococcal conjugate vaccine (PCV13) vaccine and 14/33 (42.4%) received the pneumococcal polysaccharide vaccine (PPSV23) vaccine. The total revenue and cost generated by the protocol over the 60‐day period was $8276.10 and $6406.88, respectively. The ROI for the protocol was calculated to be 29.2%. Conclusion The implementation of a pharmacy resident‐driven pneumococcal vaccination protocol increased pneumococcal vaccination rates while also serving as a revenue source. Health care systems may consider implementing a similar protocol to increase vaccination rates and provide novel revenue generating models for their institution.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

A pharmacy resident‐driven pneumococcal vaccination protocol increases vaccination rates in hospitalized patients over 65 years

Wells

Monte

Prescott

et al. 2019

J Am Coll Clin Pharm

View full text Add to dashboard Cite

show abstract

“…15 Although there are published accounts of pharmacybased immunization programs in the inpatient and clinic setting, there are no published reports that evaluate the feasibility and safety of a pharmacist-based vaccination program in the ED. 16,17 Thus, the purpose and rationale of this report is to demonstrate what we observed in terms of feasibility and safety in this pilot study involving a pharmacist-based influenza vaccination program in the ED. The primary objective of this study is to determine if screening and administering the influenza vaccine in the ED by a pharmacist is feasible.…”

Section: Introductionmentioning

confidence: 86%

Feasibility of a Pharmacy-Based Influenza Immunization Program in an Academic Emergency Department

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Pharmacists should use every opportunity to vaccinate when appropriate, including within health systems. For example, pharmacy‐based immunization programs for influenza and pneumococcal vaccines have been implemented in emergency department and hospital inpatient settings, respectively . The US Centers for Disease Control and Prevention (CDC) acknowledges and supports the important role of pharmacists in increasing vaccination rates and encourages pharmacy‐based vaccination as a method to improve adolescent vaccination rates in particular…”

Section: What Is Known and Objectivementioning

confidence: 99%

A review of the immunogenicity, safety and current recommendations for the meningococcal serogroup B vaccine, MenB‐FHbp

Alderfer

Snow

2019

J Clin Pharm Ther

View full text Add to dashboard Cite

What is known and objective This review describes invasive meningococcal disease (IMD) epidemiology in the United States, provides a brief overview of available meningococcal vaccines and discusses meningococcal serogroup B (MenB) vaccine development. Particular focus is given to the recombinant protein MenB vaccine, MenB‐FHbp (Trumenba®, bivalent rLP2086) in light of recent publication of phase 3 data; the other MenB vaccine (Bexsero®, MenB‐4C) has been recently reviewed. Current recommendations of the US Advisory Committee on Immunization Practices (ACIP) for MenB vaccination and potential barriers to immunization are also discussed. Methods Using the published literature, this article reviews the development and use of MenB‐FHbp to date, with a focus on the United States. Results and discussion Despite the availability of medical treatment, IMD is associated with significant mortality and frequently occurring serious permanent sequelae in surviving individuals. Worldwide, most IMD is caused by six serogroups (A, B, C, W, X and Y). MenB is the most common disease‐causing meningococcal serogroup in the United States and has caused several recent university‐based IMD outbreaks. MenB vaccines, including MenB‐FHbp, are available in the United States. ACIP recommends that all individuals ≥10 years of age at increased risk for meningococcal disease receive MenB vaccination; healthy individuals 16‐23 years of age are recommended MenB vaccines based on individual clinical decision‐making. MenB‐FHbp is used on a 2‐dose schedule (0, 6 months) when vaccinating healthy individuals and on a tailored 3‐dose schedule (0, 1‒2, 6 months) in cases of increased risk. What is new and conclusion Because vaccination provides the most effective protection against IMD, pharmacists are in an excellent position to offer evidence‐based vaccine information, as well as to encourage and provide meningococcal immunizations to adolescents and young adults.

show abstract

A decade of experience with an inpatient pneumococcal vaccination program

Abstract: A pneumococcal vaccination program helped a hospital meet regulatory expectations for vaccination of patients with CAP and vaccinated many other at-risk patients.

Cited by 18 publications

References 19 publications

A pharmacy resident‐driven pneumococcal vaccination protocol increases vaccination rates in hospitalized patients over 65 years

A pharmacy resident‐driven pneumococcal vaccination protocol increases vaccination rates in hospitalized patients over 65 years

Feasibility of a Pharmacy-Based Influenza Immunization Program in an Academic Emergency Department

A review of the immunogenicity, safety and current recommendations for the meningococcal serogroup B vaccine, MenB‐FHbp

Contact Info

Product

Resources

About